Nω-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistan_ce but increases mortality rates in awake canines challenged with endotoxin

Journal of Experimental Medicine

Volumn 176, Issue 4, 1992, Pages 1175-1182

  Cobb, J Perren ^a   Natanson, Charles ^a   Hoffman, William D ^a   Lodato, Robert F ^a,b   Banks, Steve ^a   Koev, Cesar A ^a   Solomon, Michael A ^a   Elin, Ronald J ^a   Hosseini, Jeanette M ^a   Danner, Robert L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; ENDOTOXIN; ENZYME INHIBITOR; N OMEGA AMINO LEVO ARGININE; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DOG; DRUG MECHANISM; ENDOTOXEMIA; ENZYME INHIBITION; HEART INDEX; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL; VASCULAR RESISTANCE;

AMINO ACID OXIDOREDUCTASES; ANALYSIS OF VARIANCE; ANIMAL; ARGININE; DOGS; ENDOTOXINS; HEART; HEART RATE; NITRIC-OXIDE SYNTHASE; OXYGEN CONSUMPTION; PULMONARY CIRCULATION; SHOCK, SEPTIC; TIME FACTORS; VASCULAR RESISTANCE;

EID: 0026674684     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.176.4.1175     Document Type: Article

References (50)

1. Ziegler, E.J., J.A. McCutchan, J. Fierer, M.P. Glauser, J.C. Sadoff, H. Douglas, and A.I. Braude. 1982. Treatment of gramnegative bacteremia and shock with human antiserum to a mutantEscherichia coli. N. Engl. J. Med.307:1225.
2. Parrillo, J.E., M.M. Parker, C. Natanson, A.F. Sufffedini, R.L. Danner, R.E. Cunnion, and F.P. Ognibene. 1990. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113:227.
3. Parker, M.M., J.H. Shelhamer, C. Natanson, D.W. Ailing, and J.E. Parrillo. 1987. Serial cardiovascular variables in survivors and non-survivors of human septic shock: heart rate as an early predictor of prognosis. Crit. Care. Med.15:923.
4. Ruokonen, E., J. Takala, A. Kari, and E. Alhava. 1991. Septic shock and multiple organ failure.Crit. Care. Med.19:1146.
5. Groenveld, A.B.J., W. Bronsveld, and L.G. Thijs. 1984. Hemodynamic determinants of mortality in human septic shock. Surgery (St. Louis).99:140.
6. Palmer, R.M.J., A.G. Ferrige, and S. Moncada. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Land.).327:524.
7. Myers, P.R., R.L. Minor Jr., R. Guerra Jr., J.N. Bates, and D.G. Harrison. 1990. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitro-cysteine than nitric oxide. Nature (Lond.).345:161.
8. Vanin, A.F. 1991. Endothelium-derived relaxing factor is a nitrosyl iron complex with thiol ligands: hypothesis. FEBS (Fed. Eur. Biochem. Soc.) Lett.289:1.
9. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem. Biophys. Res. Commun.172:1132.
10. Kilboum, R.G., and P. Belloni. 1990. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J. Natl. Cancer Inst.82:772.
11. Gross, S.S., E.A. Jaffe, R. Levi, and R.G. Kilboum. 1991. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem. Biophys. Res. Commun.178:823.
12. Radomski, M.W., R.M.J. Palmer, and S. Moncada. 1990. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl. Acad. Sci. USA.87:10043.
13. Fleming, I., G.A. Gray, C. Schott, and J.-C. Stoclet. 1991. Inducible but not constitutive production of nitric oxide by vascular smooth muscle cells. Eur. J. Pharmacol.200:375.
14. Nathan, C.F., and D.J. Stuehr. 1990. Does endothelium-derived nitric oxide have a role in cytokine-induced hypotension?J. Natl. Cancer Inst.82:726.
15. Nathan, C.F., and D.J. Stuehr. [Editorial; comment] 1991. Nitric oxide in the clinical arena. Lancet (N. Am. Ed.). 338:1560.
16. Julou-Schaeffer, G., G.A. Gray, I. Fleming, C. Schott, J.R. Parratt, and J.C. Stoclet. 1990. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am. J. Physiol.259:H1038.
17. Gray, G.A., C. Schott, G. Julou-Schaeffer, I. Fleming, J.R. Parratt, and J.C. Stoclet. 1991. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anesthetized rats. Br. J. Pharmacol. 103:1218.
18. Sakuma, I., D.J. Stuehr, S.S. Gross, C. Nathan, and R. Levi. 1988. Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. USA.85:8664.
19. G-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?Biochem. Biophys. Res. Commun.160:881.
20. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl. Acad. Sci. USA. 87:3629.
21. G-monomethyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem. Biophys. Res. Commun.178:1135.
22. Nava, E., R.M.J. Palmer, and S. Moncada. 1991. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?Lancet (N. Am. Ed.).338:1555.
23. Petros, A., D. Bennett, and P. Valance. 1991. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet (N. Am. Ed.).338:1557.
24. Geroulanos, S., J. Schilling, M. Cakmakci, H.H. Jung, and F. Largiader. 1992. Inhibition of NO synthesis in septic shock (letter). Lancet (N. Am. Ed.).339:435.
25. Tolins, J.P., and L. Raij. 1990. Modulation of systemic blood pressure and renal haemodynamic responses by endothelium-derived relaxing factor (nitric oxide). In Nitric Oxide from L-arginine: A Bioregulatory System. S. Moncada and E.A. Higgs, editors. Elsevier Science Publishing Company, Inc., New York. 463-473.
26. Walder, C.E., C. Thiemermann, and J.R. Vane. 1991. The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br. J. Pharmacol. 102:967.
27. Perrella, M.A., K.B. Hildebrand Jr., K.B. Margulies, and J.C. Burnett Jr. 1991. Endothelium-derived relaxing factor in regulation of basal cardiopulmonary and renal function. Am. J. Physiol.261:R323.
28. Chu, A., D.E. Chambers, C. Lin, W.D. Kuehl, R.M.J. Palmer, S. Moncada, and F.R. Cobb. 1991. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs. J. Clin. Invest.87:1964.
29. Hutcheson, I.R., B.J.R. Whittle, and N.K. Boughton-Smith. 1990. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br. J. Pharmacol.101:815.
30. Vatner, S.F., and E. Braunwald. 1975. Cardiovascular control mechanisms in the conscious state. N. Engl. J. Med.293:970.
31. G-amino-L-arginine on EDRF function in the rat: Evidence for continuous basal EDRF release. J. Pharmacol. Exp Ther.257:1208.
32. G-methylarginine. Biochem. Biophys. Res. Commun.170:96.
33. G-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine.Biochem. Biophys. Res. Commun.167:1037.
34. G-amino-L-arginine: a new potent antagonist of L-arginine-mediated endothelium-dependent relaxation. Biochem. Biophys. Res. Commun.168:458.
35. Natanson, C., M.P. Fink, H.K. Ballantyne, T.J. MacVittie, J.J. Conklin, and J.E. Parrillo. 1986. Gram-negative bacteremia produces both severe systolic and diastolic dysfunction in a canine model that simulates human septic shock. J. Clin. Invest.78:259.
36. Natanson, C., R.L. Danner, M.P. Fink, T.J. MacVittie, R.I. Walker, J.J. Conklin, and J.E. Parrillo. 1988. Cardiovascular performance with E. coli challenges in a canine model of human sepsis. Am. J. Physiol.254:H558.
37. Danner, R.L., C. Natanson, R.J. Elin, J.M. Hosseini, S.M. Banks, T.J. MacVittie, and J.E. Parrillo. 1990. Pseudomonas aeruginosa compared with Escherichia coli produces less endotox-emia but more cardiovascular dysfunction and mortality in a canine model of septic shock. Chest.98:1480.
38. Hoffman, W.D., S.M. Banks, D.W. Alling, P.W. Eichenholz, P.Q. Eichacker, J.E. Parrillo, and C. Natanson. 1991. Factors that determine the hemodynamic response to inhalational anesthetics. J. Appl. Physiol.70:2155.
39. Scheffe, H. 1989. The Analysis of Variance. John Wiley & Sons, Inc., New York.
40. Dunnett, C.W. 1955. A multiple comparisons procedure for comparing several treatments with a control. Journal of the American Statistical Association.50:1096.
41. Natanson, C., P.W. Eichenholz, R.L. Danner, P.Q. Eichacker, W.D. Hoffman, G.C. Kuo, S.M. Banks, T.J. MacVittie, and J.E. Parrillo. 1989. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp Med.169:823.
42. Schulz, R., J.A. Smith, J.A. Lewis, and S. Moncada. 1991. Nitric oxide synthase in cultured endocardial cells of the pig. Br. J. Pharmacol.104:21.
43. Olmsted, F., and I.H. Page. 1966. Hemodynamic changes in dogs caused by sodium pentobarbital anesthesia. Am.J. Physiol. 210:817.
44. G-methyl-L-arginine. Biochem. Biophys. Res. Commun.177:828.
45. G-nitroarginine in brain in vitro and in vivo. Biochem. Biophys. Res. Commun.176:1136.
46. De Deyn, P.P., B. Marescau, and R.L. Macdonald. 1991. Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture. Epilesy Res.8:134.
47. Shiraga, H., Y. Watanabe, and A. Mori. 1991, Guanidino compound levels in the serum of healthy adults and epileptic patients. Epilepsy Res.8:142.
48. Bland, R.D., W.C. Shoemaker, E. Abraham, and J.C. Cobo. 1985. Hemodynamic and oxygen transport patterns in surviving and nonsurviving postoperative patients. Crit. Care. Med.13:85.
49. G-monomethyl-L-arginine in vivo promotes hepatic damage in response to lipopolysaccharide. In Nitric Oxide from L-arginine: A Bioregulatory System. S. Moncada and E.A. Higgs, editors. Elsevier Science Publishing Company, Inc., New York. 275-280.
50. Fleming, I., G. Julou-Schaeffer, G.A. Gray, J.R. Parratt, and J.C. Stoclet. 1991. Evidence that an L-arginine/nitric oxide dependent elevation of tissue cyclic GMP content is involved in depression of vascular reactivity by endotoxin. Br. J. Pharmacol. 103:1047.